In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
Subscribe To Our Newsletter & Stay Updated
